2018 Oncology Pharmacy Specialty Home Study Syllabus for Recertification, Volume 2: Adult Acute Leukemia, Pharmacogenomics, Lymphoma, Multiple Myeloma Learning Objectives

Adult Acute Leukemia

1. Analyze, evaluate, and interpret the efficacy and safety data results of the RATIFY trial for midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation.
2. Evaluate the pharmacology of midostaurin, and apply clinical outcomes to patients with acute myeloid leukemia with a FLT3 mutation.
3. Design a patient-specific treatment and monitoring plan for therapy with midostaurin plus chemotherapy.

Pharmacogenomics

1. Distinguish appropriate patients who may be optimal candidates for cell-free DNA testing.
2. Compare and contrast the benefits and limitations between cell-free DNA testing and tumor genetic testing.
3. Define cell-free DNA and recognize how it may be used in the clinical management of oncology patients.

Lymphoma

1. Analyze, evaluate, and interpret efficacy and safety data for a chemoimmunotherapy regimen used in the treatment of Hodgkin lymphoma.
2. Design an appropriate patient-specific treatment, supportive care, and monitoring plan for patients with Hodgkin lymphoma.
3. Identify and manage potential toxicities associated with a chemoimmunotherapy regimen used in the treatment of Hodgkin lymphoma.

Multiple Myeloma

1. Analyze, evaluate, and interpret clinical outcomes data for chemotherapy regimens used for the treatment of multiple myeloma.
2. Use patient-specific clinical data for appropriate therapeutic treatment recommendations in multiple myeloma.
3. Identify and manage potential toxicities associated with chemotherapy agents used for the treatment of multiple myeloma.

2018 Oncology Pharmacy Specialty Home Study Syllabus for Recertification, Volume 2: Breast Cancer, Hepatocellular Carcinoma, Lung Cancer, Prostate Cancer Learning Objectives

Breast Cancer

1. Describe optimal adjuvant bone-modifying regimens for patients receiving adjuvant therapy for breast cancer to reduce metastasis and/or recurrence and improve survival.
2. Identify potential adverse effects with the use of adjuvant bone-modifying agents in patients with breast cancer.
3. Apply guideline recommendations to individual patients receiving adjuvant therapy for breast cancer.

Hepatocellular Carcinoma

1. Analyze, evaluate, and interpret clinical outcomes data for the use of regorafenib for the treatment of hepatocellular carcinoma.
2. Identify and manage the potential toxicities associated with regorafenib for the treatment of hepatocellular carcinoma.
3. Use patient-specific clinical data for appropriate therapeutic treatment recommendations for hepatocellular carcinoma.

Lung Cancer

1. Compare and contrast the efficacy of osimertinib and gefitinib/erlotinib in EGFR-mutated non–small cell lung cancer.
2. Determine the safety profile of osimertinib compared with gefitinib/erlotinib.
3. Identify the appropriate patient population to be treated with osimertinib in untreated EGFR-mutated non–small cell lung cancer.

Prostate Cancer

1. Explain the mechanism of action of abiraterone in the treatment of prostate cancer.
2. Discuss the characteristics of patients most likely to benefit from abiraterone.
3. Describe the efficacy, dosing, administration, and toxicity profile of abiraterone that patients with prostate cancer may experience.